Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: An open-label study

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 7, 2015, Pages 961-970

  Chung, Sun Ju ^a   Kim, Jong Min ^b   Kim, Jae Woo ^c   Jeon, Beom Seok ^d   Singh, Pritibha ^e   Thierfelder, Stephan ^e   Ikeda, Junji ^f   Bauer, Lars ^e  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Dong A University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e UCB PHARMA   (Belgium)

^f OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Parkinson's disease; Pramipexole; Ropinirole; Rotigotine transdermal system; Safety

Indexed keywords

BENSERAZIDE; CARBIDOPA; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; INDOLE DERIVATIVE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ABNORMAL DREAMING; ADULT; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; ERYTHEMA; EVENING DOSAGE; FEASIBILITY STUDY; FEMALE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 4 CLINICAL TRIAL (TOPIC); PITTSBURGH SLEEP QUALITY INDEX; PRURITUS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TRANSDERMAL PATCH; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING; CLINICAL TRIAL; INTRADERMAL DRUG ADMINISTRATION; PHASE 4 CLINICAL TRIAL; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DRUG SUBSTITUTION; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84928559916     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1030336     Document Type: Article

References (19)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(11 Suppl 5):S1-S88
2. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013;20(1):5-15
3. Junghanns S, Gleockler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004;251(Suppl 6):VI/19-23
4. Reichmann H, Herting B, Miller A, et al. Switching and combining dopamine agonists. J Neural Transm 2003;110(12):1393-400
5. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 2006;28(1):1-12
6. Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379(1):73-86
7. Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34(4):966-78
8. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303(2):791-804
9. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57(6):701-12
10. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22(16):2398-404
11. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68(4):272-6
12. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68(16):1262-7
13. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6(6):513-20
14. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26(1):90-9
15. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 1999;52(6):1227-9
16. Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. J Neural Transm 1999;106(9-10):925-9
17. Kim HJ, Jeon BS, Lee WY, et al. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol 2011;11:100
18. LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007;30(5):256-65
19. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement disorders 2010;25(15):2649-53